How Hypertrophic Cardiomyopathy Progresses in Adults
Hypertrophic cardiomyopathy is the most common form of genetic heart disease worldwide. Researchers have estimated that up to 1 in 200 people have the condition, which is characterized by an abnormal thickening of the walls of the heart. This thickening can make it difficult for the heart to pump blood.
Hypertrophic cardiomyopathy can be a deadly disease, and there was a time when it was largely untreatable. But the last 20 years have witnessed a sea change in the condition’s management—a change that has led to an estimated 10-fold decrease in deaths.
[time-brightcove not-tgx=”true”]
“...
Source: TIME: Health - March 27, 2024 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance healthscienceclimate Source Type: news
Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension
(MedPage Today) -- The FDA approved sotatercept (Winrevair) for treating pulmonary arterial hypertension (PAH) in adults, Merck announced on Tuesday.
A novel activin signaling inhibitor, sotatercept is indicated to increase exercise capacity... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - March 27, 2024 Category: Urology & Nephrology Source Type: news
Why Is Merck Stock Trading Higher On Wednesday?
Tuesday, the FDA approved Merck & Co Inc’s MRK Winrevair (sotatercept-csrk), for injection, 45mg, 60mg for adults with pulmonary arterial hypertension (PAH) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. PAH is high blood…#fda #merckcoincs #pah #fc #merck #acceleronpharmainc #winrevair #healthcare #schott (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2024 Category: Consumer Health News Source Type: news
Sleep Troubles Can Raise Your Blood Pressure: Study
WEDNESDAY, March 27, 2024 -- A major review of data confirms that getting less than the recommended amount of sleep each night is a risk factor for high blood pressure.
Data collected in 16 studies conducted from 2000 through 2023, involving over 1... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2024 Category: General Medicine Source Type: news
Young Adults With Migraine May Face Higher Stroke Risk
WEDNESDAY, March 27, 2024 -- Migraines in young adults appear to increase their risk of stroke more than traditional risk factors like high blood pressure, a new study reports.
Results show that migraine is the most important non-traditional risk... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 27, 2024 Category: General Medicine Source Type: news
FDA Approves Winrevair (sotatercept-csrk) a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension
RAHWAY, N.J.--(BUSINESS WIRE) March 26, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name:... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 26, 2024 Category: Drugs & Pharmacology Source Type: news
Amazon Pharmacy: AI aiding same-day delivery to New York, Los Angeles
Customers in New York City and greater Los Angeles who need medication to manage flu, high blood pressure, diabetes, and other common conditions can now get their medications delivered to their door within hours. Amazon Pharmacy has launched Same-Day Delivery of prescription medication in New York…#newyorkcity #amazonpharmacy #samedaydelivery #austin #indianapolis #miami #phoenix #seattle #collegestation #amazonpharmacys (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2024 Category: Consumer Health News Source Type: news
Merck's $11.5 Billion Bet on Its Next Big Drug Finally Arrives
The newly approved drug, which treats potentially fatal pulmonary arterial hypertension, is estimated to ring up as much as $7.5 billion in yearly sales. (Source: Reuters: Health)
Source: Reuters: Health - March 26, 2024 Category: Consumer Health News Source Type: news
US FDA Approves Merck's Therapy for Rare Lung Condition US FDA Approves Merck's Therapy for Rare Lung Condition
The U.S. Food and Drug Administration on Tuesday approved Merck ' s treatment for adults with high blood pressure due to constriction of lung arteries, adding another...Reuters Health Information (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 26, 2024 Category: Cardiology Tags: Pulmonary Medicine Source Type: news
Merck Drug for Rare High Blood Pressure Disorder Approved in US
(Source: Reuters: Health)
Source: Reuters: Health - March 26, 2024 Category: Consumer Health News Source Type: news
FDA Approves Merck ’s New Drug For A Rare Lung Disease
The pharmaceutical giant ’s new treatment, sotatercept, showed significant benefits for the thousands of patients suffering from pulmonary arterial hypertension in clinical trials. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 26, 2024 Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick Premium Content premiumcontent technology alexknappblog Source Type: news
Rwanda: Kayonza Survey - 10 Percent of Patients With NCDs Unknowingly Have Chronic Kidney Disease
[New Times] A team of doctors and nurses from Rwinkwavu Hospital and Partners in Health collected blood and urine samples to study the occurrence of chronic kidney disease in 1,268 patients with hypertension, 1,189 with HIV, and 582 with other non-communicable diseases (NCDs) across two phases. The study revealed that more than 300 patients out of 3,039 tested positive for chronic kidney disease. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 26, 2024 Category: African Health Tags: Central Africa East Africa Health and Medicine Rwanda Source Type: news
Fixed-Dose Macitentan/Tadalafil Combo Gets FDA Approval for PAH
(MedPage Today) -- FDA approved macitentan/tadalafil (Opsynvi) as the first single-tablet combination therapy targeting multiple pathways for pulmonary arterial hypertension (PAH), Johnson & Johnson announced.
The fixed-dose combination of... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 25, 2024 Category: American Health Source Type: news
U.S. FDA Approves OPSYNVI ® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for early use of combination therapy.1 The comprehensive PAH... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 22, 2024 Category: Pharmaceuticals Tags: FDA Source Type: news
FDA Approves Opsynvi (macitentan and tadalafil) for Adults with Pulmonary Arterial Hypertension
RARITAN, NJ, March 22, 2024– Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Opsynvi®– a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 22, 2024 Category: Drugs & Pharmacology Source Type: news
